Curated News
By: NewsRamp Editorial Staff
May 21, 2025
Silo Pharma Collaborates on Drug-Device Study for PTSD Treatment Delivery
TLDR
- Silo Pharma gains advantage in PTSD treatment with microchip-enabled nasal spray system, bypassing blood-brain barrier for faster delivery.
- Silo Pharma partners with Resyca BV for drug-device study on SPC-15, providing final device data for FDA's IND application.
- Silo Pharma's innovative treatment approach aims to improve mental health by enhancing therapeutic delivery and addressing underserved conditions.
- Silo Pharma's collaboration for faster, safer drug delivery through nasal spray system showcases cutting-edge advancements in PTSD treatment.
Impact - Why it Matters
This news matters as it showcases Silo Pharma's innovative approach to addressing underserved conditions like PTSD and chronic pain. The collaboration with Resyca BV could potentially lead to a breakthrough in therapeutic delivery methods, impacting patients suffering from stress-induced psychiatric disorders.
Summary
Silo Pharma (NASDAQ: SILO) has entered into a service agreement with Resyca BV to conduct a drug-device study on its microchip-enabled nasal spray system for its lead PTSD treatment candidate, SPC-15. CEO Eric Weisblum highlighted the device's potential to deliver therapeutics faster and safer by bypassing the blood-brain barrier. Silo is also advancing two other SPC-15 studies, including a toxicology study and a large animal safety trial requested by the FDA.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Collaborates on Drug-Device Study for PTSD Treatment Delivery
